Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events

ME Staff 8-k
-
0

Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Other Events
Item 8.01.Other Events.

On August2, 2017, Agile Therapeutics,Inc. (“Agile”) updated its corporate presentation that it intends to use in connection with presentations at conferences and meetings with investors.

A copy of Agile’s presentation is attached hereto as Exhibit99.1 and is hereby incorporated by reference herein.

Item 8.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Agile Therapeutics,Inc. Presentation.


AGILE THERAPEUTICS INC Exhibit
EX-99.1 2 a17-18496_3ex99d1.htm EX-99.1 Exhibit 99.1   A Forward Thinking Women’s Health Company NASDAQ: AGRX 1   Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include “forward-looking statements”. We may,…
To view the full exhibit click here

About Agile Therapeutics,Inc. (NASDAQ:AGRX)

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.